NCT01317667已完成1 期
Phase 1 Escalating, Multiple-Dose Study to Evaluate the Safety and Immunogenicity of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc™) in Healthy Adults
U.S. Army Medical Research and Development Command2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2011年3月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Number of Vaccinated Subjects Any Averse Events and by Location and Severity
研究概览
简要总结
This study is a Phase 1, escalating, multiple-dose, single-center study to evaluate the safety and immunogenicity of the RVEc vaccine.
The two principal hypotheses to be tested are: RVEc vaccine will display an acceptable safety profile as determined by adverse event data and RVEc vaccine will elicit ELISA immunoglobulin G (IgG) titers greater than or equal to 1:500 and toxin-neutralizing antibody (TNA) anti-ricin toxin-neutralizing antibody titers greater than or equal to 1:50 in vaccine recipients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Study subjects must be 18-50 years old.
- •Subjects must weigh at least 110 pounds.
- •Subjects must be in good health as judged from medical history, physical examination, EKG and chest x-ray, complete blood count (CBC) with differential, clinical chemistries, urinalysis, hepatitis serology, and HIV antibody test, and be medically cleared for participation by an investigator. If any HIV or hepatitis testing is positive, the individual will be provided with counseling and referral for health care.
- •Females of childbearing potential must have a negative pregnancy test on vaccination day before each dose and agree to not become pregnant or breastfeed for 3 months after the last dose of the vaccine and be willing to use a reliable form of contraception during the study.
- •Study subjects must read and sign an approved informed consent.
- •Study subjects must be willing to complete a subject diary card after each vaccination.
- •Study subjects must be willing to return for all follow-up visits.
- •Study subjects must agree to report any adverse event (AE) that may or may not be associated with administration of the investigational product through the 9-month follow-up visit. Study subjects will report all serious adverse events for the duration of the study.
排除标准
- •Body weight less than 110 pounds.
- •Acute or chronic medical conditions or immunodeficiency from a medical condition or medical treatment, medications, or dietary supplements that, in the investigator's opinion, would impair the subject's ability to respond to vaccination.
- •Severe hypersensitivity to any vaccine (anaphylaxis, angioedema, bronchospasm, or laryngospasm).
- •History of asthma, chronic obstructive pulmonary disease, or other current/residual disease of the lungs.
- •Clinically significant abnormal laboratory tests.
- •Current smoker.
- •Any known allergies to sodium succinate, Tween-20 (a detergent), aluminum hydroxide, or kanamycin.
- •Previously received ricin toxin vaccine or has antibodies to ricin toxin proteins.
- •Receipt of licensed vaccines within 30 days prior to the start of the study or plans to receive other vaccines during the initial 9 months of the study (the only exceptions are the inactivated influenza vaccine that can be received at least 30 days after RVEc Dose 3).
- •Receipt of investigational drug/test product within 30 days prior to entry or within the initial 9 months of the study.
- •Females: Pregnant or breastfeeding.
- •Enrolled in another greater than minimal risk study.
结局指标
主要结局
Number of Vaccinated Subjects Any Averse Events and by Location and Severity
时间窗: Days 1, 3, 7, 14, and 28 after each vaccination and at 6 and 9 months
次要结局
- Over Response Rates and Comparisons for ELISA and TNA Titers(Day 7, 14, 28, 35, 42, 56, 63, 70, 84, month 6, 9, and 12)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsCervical CarcinomaPancreatic CarcinomaTriple Negative Breast CancerUrothelial CarcinomaSquamous Cell Carcinoma of the Head and NeckHepatocellular CarcinomaMelanomaRenal Cell CarcinomaNon-small Cell Lung CarcinomaSmall Cell Lung CarcinomaGastric or Gastroesophageal Junction AdenocarcinomaAdvanced or Metastatic Solid TumorsProstate CarcinomaFallopian Tube CancerPrimary Peritoneal CarcinomaSquamous Cell Anal CancerSquamous Cell Penile CarcinomaSquamous Cell Vulvar CarcinomaColorectal CarcinomaEndometrial CarcinomaIntrahepatic CholangiocarcinomaEpithelial Ovarian CancerNasopharyngeal CarcinomaNCT03849469Xencor, Inc.78
已完成
1 期
Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid ArthritisSystemic Lupus ErythematosusRheumatoid ArthritisNCT03334851Pfizer74
尚未招募
1 期
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid TumorsMetastatic TumorAdvanced Solid TumorCervix CancerHead and Neck Squamous Cell CarcinomaOvarian CancerRenal Cell CarcinomaNasopharyngeal CarcinomaNCT06383507Zhejiang University18
已完成
1 期
Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B PatientsHemophilia BNCT03186677ISU Abxis Co., Ltd.11
招募中
1 期
A Study of ASKG315 in Patients With Advanced Solid Tumors.Advanced Solid TumorsNCT05554666AskGene Pharma, Inc.56